SCHEMBL478183

SCHEMBL478183

CCC(=O)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.66
GSK3B P49841 2/20 0.66
CES2 O00748 1/20 0.59
CES1 P23141 1/20 0.59
MMP1 P03956 1/20 0.56
MMP2 P08253 1/20 0.54
MMP8 P22894 1/20 0.54
MAPT P10636 2/20 0.53
ALDH1A1 P00352 1/20 0.53
SRD5A2 P31213 2/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
HSD11B1 P28845 1/20 0.51
HDAC1 Q13547 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
NR4A1 P22736 1/20 0.50
NR4A2 P43354 1/20 0.50
NR4A3 Q92570 1/20 0.50
PDPK1 O15530 1/20 0.49
HRH3 Q9Y5N1 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2269889 0.94 MAPT (0.61) PTPN1GSK3BCES2CES1MMP1
SCHEMBL6602154 0.85 PTPN1 (0.62) PTPN1GSK3BCES2CES1MMP1
SCHEMBL2764867 0.84 MMP1 (0.62) PTPN1GSK3BCES2CES1MMP1
SCHEMBL27787625 0.84 PTPN1 (0.49) PTPN1GSK3BCES2CES1MMP1
SCHEMBL26135918 0.83 MMP1 (0.76) PTPN1GSK3BCES2CES1MMP1
SCHEMBL29987081 0.83 PTPN1 (0.75) PTPN1GSK3BCES2CES1MMP1
SCHEMBL8051337 0.82 SMN1; SMN2 (0.70) GSK3BMAPTALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL2634195 0.81 HTR7 (0.66) PTPN1GSK3BCES2CES1MMP1
SCHEMBL965418 0.81 RAB9A (0.63) MAPTALDH1A1SRD5A2SMN1; SMN2L3MBTL1
SCHEMBL2074662 0.81 PTPN1 (0.68) PTPN1GSK3BCES2CES1MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108083999-B Green preparation method of alpha-hydroxyketone 西北师范大学 2020-08-11 CN claimed
US-9201318-B2 Polymer for charge generation layer and charge transport layer formulation XEROX CORPORATION (US) 2015-12-01 US claimed
US-20150024310-A1 POLYMER FOR CHARGE GENERATION LAYER AND CHARGE TRANSPORT LAYER FORMULATION XEROX CORPORATION 2015-01-22 US claimed
US-8877413-B2 Flexible imaging members comprising improved ground strip XEROX CORPORATION (US) 2014-11-04 US claimed
US-8614038-B2 Plasticized anti-curl back coating for flexible imaging member XEROX CORPORATION (US) 2013-12-24 US claimed
US-20130216266-A1 IMAGING MEMBERS COMPRISING FLUOROKETONE XEROX CORPORATION (US) 2013-08-22 US claimed
US-20130202995-A1 PLASTICIZED ANTI-CURL BACK COATING FOR FLEXIBLE IMAGING MEMBER XEROX CORPORATION (US) 2013-08-08 US claimed
US-20130052576-A1 FLEXIBLE IMAGING MEMBERS COMPRISING IMPROVED GROUND STRIP XEROX CORPORATION (US) 2013-02-28 US claimed
US-8343700-B2 Imaging members having stress/strain free layers XEROX CORPORATION (US) 2013-01-01 US claimed
US-8232030-B2 Curl-free imaging members with a slippery surface XEROX CORPORATION (US) 2012-07-31 US claimed
US-20110256474-A1 IMAGING MEMBERS HAVING STRESS/STRAIN FREE LAYERS XEROX CORPORATION (US) 2011-10-20 US claimed
US-20110229808-A1 CURL-FREE IMAGING MEMBERS WITH A SLIPPERY SURFACE XEROX CORPORATION (US) 2011-09-22 US claimed
US-20110136049-A1 IMAGING MEMBERS COMPRISING FLUOROKETONE XEROX CORPORATION (US) 2011-06-09 US claimed
JP-1019033-A None JP disclosed
JP-11343259-A None JP disclosed
US-12486218-B2 Compounds advantageous in the treatment of central nervous system diseases and disorders AURIMMED PHARMA, INC. (US) 2025-12-02 US disclosed
EP-0158448-A2 Azolyl propanols IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1985-10-16 EP disclosed
EP-0092239-A2 Oxazole derivatives, production and use thereof Takeda Chemical Industries, Ltd. (JP) 1983-10-26 EP disclosed
US-4293552-A Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas ELI LILLY AND COMPANY (US) 1981-10-06 US disclosed
US-4160834-A INSECTICIDES ELI LILLY AND COMPANY (US) 1979-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12486218-B2 Compounds advantageous in the treatment of central nervous system diseases and disorders SMN1; SMN2, HDAC6, CTSA PTPN1 3902/4885GSK3B 45/4885CES2 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.